Publication | Closed Access

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

Interim AnalysisOncologyBevacizumab Versus ErlotinibPathologyImmune Checkpoint InhibitorCancer TreatmentMedicineRadiation OncologyLung CancerMolecular OncologyPhase 3